Built for medical-spa owners. Only.
Inside MedSpa is a daily intelligence brief for the people who own aesthetic practices — not patients, not vendors, not the general beauty press. Every item is filtered to one test: does this touch your money, your license, or your patients' demand?
How we pick what matters
There's no shortage of medical-aesthetics noise — press releases, generic pharma wire, marketing listicles. Most of it isn't for an owner. We cut hard against three filters, and an item has to clear at least one:
Your money. Injectable pricing and supply, manufacturer rebate and loyalty programs (Allē, Aspire, Evolus Rewards), device pricing and financing, the moves of the companies you buy from.
Your license. Scope-of-practice and supervision rules, good-faith-exam requirements, injector regulation, board actions, and enforcement against unlicensed operators.
Your patients' demand. The trends that change what people walk in asking for — GLP-1 and facial volume, new indications, demand shifts you can build an offer around.
If an item doesn't change a decision an owner makes about pricing, compliance, hiring, purchasing, or positioning, it doesn't run. Generic "5 marketing tips" is exactly what we leave out.
The primary sources we monitor
We don't rehash other people's blogs. We read the primary record directly and continuously, the same documents the regulators and the public companies file:
- FDA openFDA — device 510(k) clearances, drug & device recalls, and enforcement actions, pulled straight from the agency's own databases.
- SEC EDGAR — full-text filings and 8-Ks from the public aesthetics companies: AbbVie/Allergan Aesthetics, Galderma, Evolus, Revance, InMode, Cutera, Hims & Hers, and the GLP-1 makers (Lilly, Novo Nordisk).
- Federal Register — proposed and final federal rules touching injectables, devices, and compounding.
- ClinicalTrials.gov & PubMed / NIH — new indications, pivotal trials, and the evidence behind the treatments on your menu.
- State medical & nursing boards — scope-of-practice, supervision, and good-faith-exam rules, tracked state by state in our regulation tracker.
- Public market data — closing prices and corporate events for the companies whose moves hit your supply, pricing, and competition.
Our role is judgment: we read the firehose so you don't, and hand you only the few things that actually changed something — with the context to know what to do.
Independent by design
Most "medspa news" is published by companies that sell something to medspas — booking software, devices, financing. Their content has to end in a demo. We sell none of those things. Inside MedSpa's only product is the brief itself, which means our comparisons of software, devices, and injectables answer to you, not to an advertiser. Featured partnerships, when they exist, are always labeled and never shape editorial judgment.
How it's made
Inside MedSpa runs on a purpose-built intelligence engine — an AI we coded and tuned specifically for medical aesthetics and wired directly into the primary record above. It's not a generic chatbot pointed at the news; it's a custom system built for one industry. Every morning it reads the day's sources and drafts the brief. A relevance gate strips anything that isn't unmistakably owner-relevant, and a verification step holds any item whose facts or product names don't trace cleanly to a cited source. The AI buys speed and total coverage; the engineering buys trust. We'd rather run four things that matter than forty that don't.
Accuracy & corrections
We aim to be first and right, and we link the underlying source on news items so you can verify for yourself. We are a general business publication, not your lawyer or accountant — regulatory specifics in particular should be confirmed with your state boards or counsel before you act. Spot something wrong or out of date? Email editor@insidemedspa.com and we'll correct it fast.
Get the daily brief — $20/mo Read a sample first →
Inside MedSpa is a general, impersonal publication for medical-aesthetics business owners. It is not individualized business, financial, medical, or legal advice. Any market or company information is general in nature and not a recommendation.